Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report. With upcoming BEXMAB read-outs, a planned pivotal study and a potential license deal on the horizon, we see promising times ahead for the company. Following the company’s recent clinical progression, positive FDA feedback and a granted Fast Track Designation, we increase our base case valuation to EUR2.8 (2) per share.